Sugi Predict

Sugi Predict / Compounds / SCHEMBL810368

SCHEMBL810368

SCHEMBL810368

Nc1ccc(OCc2ccccc2)cc1[N+](=O)[O-]

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 3/20 0.53
▸ MEN1 O00255 2/20 0.53
▸ KMT2A Q03164 2/20 0.53
▸ NPC1 O15118 1/20 0.53
▸ ATM Q13315 1/20 0.53
▸ CTSV O60911 2/20 0.52
▸ CTSL P07711 2/20 0.52
▸ MAPT P10636 5/20 0.51
▸ PTGES O14684 1/20 0.51
▸ MAOB P27338 3/20 0.50
▸ MAOA P21397 2/20 0.50
▸ AR P10275 1/20 0.50
▸ GAA P10253 1/20 0.50
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ L3MBTL1 Q9Y468 1/20 0.50
▸ BACE1 P56817 1/20 0.49
▸ TLR4 O00206 1/20 0.49
▸ TLR2 O60603 1/20 0.49
▸ ALDH1A1 P00352 3/20 0.49
▸ LMNA P02545 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30040863 1.00 RAB9A (0.53) RAB9AMEN1KMT2ANPC1ATM
SCHEMBL1708317 0.88 MAPT (0.64) RAB9AMEN1KMT2ANPC1ATM
SCHEMBL5036438 0.86 CA12 (0.51) RAB9AMEN1KMT2ANPC1ATM
SCHEMBL1663438 0.86 MEN1 (0.57) RAB9AMEN1KMT2ANPC1ATM
SCHEMBL30832846 0.86 MEN1 (0.57) RAB9AMEN1KMT2ANPC1ATM
SCHEMBL214372 0.86 MAPT (0.62) RAB9AMEN1KMT2ANPC1ATM
SCHEMBL6643739 0.86 MAOB (0.50) MEN1KMT2AMAPTMAOBMAOA
SCHEMBL5087371 0.86 ALDH1A1 (0.53) MEN1KMT2AMAPTPTGESMAOB
SCHEMBL28095853 0.86 MAPT (0.53) RAB9AMEN1KMT2ANPC1MAPT
SCHEMBL4314849 0.84 MAPT (0.54) RAB9AMEN1KMT2ANPC1ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9287568-B2 High performance, high durability non-precious metal fuel cell catalysts 3M INNOVATIVE PROPERTIES COMPANY (US) 2016-03-15 — — US claimed
CN-101657921-B High performance, high durability non-precious metal fuel cell catalysts 3M INNOVATIVE PROPERTIES CO US 2013-06-12 — — CN claimed
US-20110319257-A1 HIGH PERFORMANCE, HIGH DURABILITY NON-PRECIOUS METAL FUEL CELL CATALYSTS 3M INNOVATIVE PROPERTIES COMPANY 2011-12-29 — — US claimed
EP-2135313-B1 HIGH PERFORMANCE, HIGH DURABILITY NON-PRECIOUS METAL FUEL CELL CATALYSTS 3M INNOVATIVE PROPERTIES CO (US) 2011-09-14 — — EP claimed
CN-101657921-A High-performance, high durability non-precious metal fuel cell catalysts 3M INNOVATIVE PROPERTIES CO US 2010-02-24 — — CN claimed
EP-2135313-A1 HIGH PERFORMANCE, HIGH DURABILITY NON-PRECIOUS METAL FUEL CELL CATALYSTS 3M Innovative Properties Company (US) 2009-12-23 — — EP claimed
WO-2008127828-A1 HIGH PERFORMANCE, HIGH DURABILITY NON-PRECIOUS METAL FUEL CELL CATALYSTS 3M INNOVATIVE PROPERTIES COMPANY (US) 2008-10-23 — — WO claimed
CN-118324653-A Compound, metal compound, preparation method and application thereof, contrast agent and imaging method 四川大学 2024-07-12 — — CN disclosed
CN-118221679-A Benzo [ b ] [1,4] diazepine [4,5-e ] tetrazole derivative and pharmaceutically acceptable salt, preparation method and application thereof 常熟理工学院 2024-06-21 — — CN disclosed
US-20240166693-A1 METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPY 1 Design Therapeutics, Inc. 2024-05-23 — — US disclosed
WO-2024029819-A1 PHARMACEUTICAL COMPOSITION CONTAINING BENZIMIDAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND METHOD FOR PREPARING SAME 경희대학교 산학협력단 2024-02-08 — — WO disclosed
CN-117279636-A Methods and compounds for modulating myotonic muscular dystrophy type 1 设计治疗公司 2023-12-22 — — CN disclosed
EP-4259133-A1 METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPHY 1 Design Therapeutics, Inc. (US) 2023-10-18 — — EP disclosed
US-5446059-A Treating or preventing inflammatory or immunoallergic conditions CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) 1995-08-29 — — US disclosed
EP-0643701-A1 BENZIMIDAZOLE-DERIVED COMPOUNDS, METHOD FOR PREPARING SAME, AND THERAPEUTICAL AND COSMETIC USES THEREOF CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA, ( CIRD GALDERMA) (FR) 1995-03-22 — — EP disclosed
WO-1992021663-A1 BENZIMIDAZOLE-DERIVED COMPOUNDS, METHOD FOR PREPARING SAME, AND THERAPEUTICAL AND COSMETIC USES THEREOF CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) 1992-12-10 — — WO disclosed
US-4080461-A PESTICIDES, FUNGICIDES SYNTEX (U.S.A.) INC. (US) 1978-03-21 — — US disclosed
US-4072696-A 5(6)-Benzene ring substituted benzimidazole-2-carbamate derivatives having anthelmintic activity SYNTEX (U.S.A.) INC. (US) 1978-02-07 — — US disclosed
US-4002640-A ANTIFUNGAL AGENTS SYNTEX (U.S.A.) INC. (US) 1977-01-11 — — US disclosed
US-3935314-A Anti-hypertensive compositions of benzimidazole derivatives BEECHAM GROUP LIMITED (EN) 1976-01-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240166693-A1 METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPY 1 MTPN, DMPK, MBNL1 RAB9A 4424/4885MEN1 3905/4885KMT2A 2132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.